SpringWorks <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Approval of Merger Agreement with <a href="https://laohu8.com/S/MKGAF">Merck KGaA</a>, Expects Completion in Second Half of 2025
SpringWorks Therapeutics Inc. has announced an update regarding its merger with Merck KGaA, Darmstadt, Germany. According to the company, the Merger Agreement, which was initially disclosed on April 27, 2025, has been approved by SpringWorks' board of directors. Under the agreement, EMD Holdings Merger Sub, Inc., a wholly owned subsidiary of Merck KGaA, will merge with SpringWorks, resulting in SpringWorks becoming a wholly owned subsidiary of Merck KGaA. The merger is anticipated to be completed in the second half of 2025, pending satisfaction of customary closing conditions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SpringWorks Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-059579), on June 16, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。